Androderm (Testosterone Transdermal System)
Company: TheraTech
Approval Status: Approved on September 29, 1995
Treatment for: hypogonadism
Areas: Cardiology/Vascular Diseases; Endocrinology
| General Information | Clinical Results | Side Effects | Additional Information |
General Information
Clinical Results
In clinical trials, Androderm restored normal testosterone levels in 86 of 94 subjects who completed the trials.Side Effects
The most common side effects reported were temporary mild-to-moderate redness or itching at patch sites.Additional Information
A previously approved patch, Androderm can be placed on different parts of the body. Transdermal patches offer alternatives to testosterone injections, a therapy administered every two to four weeks that can create abnormal highs and lows in hormone levels.
Only about 5% of the estimated 4 million to 5 million American men with hypogonadism currently receive testosterone replacement therapy. Symptoms of the disorder include sexual dysfunction (loss of libido or impotence), fatigue, depressed mood, muscle wasting, osteoporosis, or absence or regression of secondary male sexual characteristics (muscle development, deep voice, or hair distribution).
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Medical Dictionary Searches
